Take-home naloxone administered in emergency settings: feasibility of intervention implementation in a cluster randomized trial.  Snooks HA, Jones JK, Bell FB, Benger JR, Black SL, Dixon S, Edwards A, Emery H, Evans BA, Fuller GW, Goodacre S…

Improving Naloxone Co-prescribing Through Clinical Decision Support.  Cramer E, Kuperman E, Meyer N, Blum J.  Cureus. 2024 Jul 5;16(7):e63919. doi: 10.7759/cureus.63919. PMID: 39099893; PMCID: PMC11298243. https://www.ncbi.nlm.nih.gov/p…

A Case Report of Delayed Opioid Toxidrome After Administration of Naloxone.  Cowan M, Kumar P, McManus J, Bilodeau S, Beck A.  Clin Pract Cases Emerg Med. 2024 Aug;8(3):222-225. doi: 10.5811/cpcem.6622. PMID: 39158236; PMCID: PMC11326049…

Naloxone and Patient Outcomes in Out-of-Hospital Cardiac Arrests in California.  Dillon DG, Montoy JCC, Nishijima DK, et al.  JAMA Netw Open. 2024;7(8):e2429154. doi:10.1001/jamanetworkopen.2024.29154 https://jamanetwork.com/journa…

Nalmefene Auto-Injector: Concerns About the New Opioid Overdose Antidote Explained The first nalmefene hydrochloride (HCl) auto-injector (Zurnai) brings a new tool to the fight against the opioid overdose epidemic but is not without controversy.&nb…

A tale of two opioid antidotes NEW OVERDOSE REVERSAL MED — The FDA this week approved a new product to reverse opioid overdoses, but some harm-reduction experts say it’s an unnecessary tool that could pose more risks than benefits. (Politico, USA…